Skip to content

The Effectiveness of Transcranial Magnetic Stimulation and Mirror Therapy in Hemispatial Neglect

Evaluation of the Effectiveness of Transcranial Magnetic Stimulation and Mirror Therapy in Hemispatial Neglect Developing After Stroke

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07228871
Enrollment
22
Registered
2025-11-14
Start date
2026-01-01
Completion date
2027-01-31
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemispatial Neglect

Keywords

neglect, mirror therapy, theta burst stimulation

Brief summary

The aim of this study is to evaluate the effectiveness of continuous Theta Burst Stimulation added to mirror therapy on neglect associated with stroke.

Interventions

OTHERMirror Therapy

Mirror therapy will be administered 5 days a week for 2 weeks.

DEVICEcTBS

Patients received cTBS applied to the P3 region according to the 10/20 electroencephalogram system for 5 days a week, totalling 10 sessions over 2 weeks.

OTHERCognitive rehabilitation

Methods that facilitate adaptation in daily life activities will be taught.

Sponsors

Ankara Etlik City Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Ischemic/haemorrhagic stroke 2. Right hemisphere lesion 3. Patients with a duration of more than 7 days but less than 1 year from the date of the event 4. Aged between 18 and 75 years 5. Patients with a Mini Mental Test Score ≥ 24

Exclusion criteria

1. History of recurrent stroke 2. Presence of vision or hearing problems 3. Use of medication affecting cognitive function 4. History of epilepsy 5. Pregnancy or breastfeeding 6. History of malignancy 7. Pacemaker 8. Presence of metallic implants in the brain or scalp (including cochlear implant) 9. History of premorbid dementia 10. Presence of psychiatric or additional neurological disease

Design outcomes

Primary

MeasureTime frame
Catherine Bergego ScaleBefore Treatment and 2nd week of treatment

Secondary

MeasureTime frame
Verbal and Nonverbal Cancellation TestBefore Treatment and 2nd week of treatment
Line Bisection TestBefore Treatment and 2nd week of treatment
Barthel IndexBefore Treatment and 2nd week of treatment

Countries

Turkey (Türkiye)

Contacts

CONTACTAyşe Naz Kalem Özgen, specialist
kalemnaz@gmail.com+90 0312 797 00 00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026